Trial
NCT03316872
Study of Pembrolizumab and Radiotherapy in Liver Cancer
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
University Health Network, Toronto
Collaborators
—
Condition
Hepatocellular Carcinoma
Intervention
Pembrolizumab
Why stopped
The study was stopped due to the shift in systemic treatment paradigm for HCC precluding further enrolment.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-07-25